Publications by authors named "Aarti Mane"
Article Synopsis
- The study aimed to investigate how metformin affects the plasma levels of tuberculosis drugs (rifampicin, isoniazid, and pyrazinamide) in patients undergoing standard antituberculosis treatment (ATT) and the role of specific gene polymorphisms on drug metabolism.
- In a phase IIB clinical trial, non-diabetic adults with pulmonary tuberculosis were divided into two groups: one receiving standard ATT and the other receiving ATT plus metformin; pharmacokinetic measurements were taken to assess drug levels.
- Results indicated that metformin increased the clearance of rifampicin, isoniazid, and pyrazinamide, particularly in patients with certain genetic variants, though it had minimal impact on treatment
Background: Metformin, by reducing intracellular Mycobacterium tuberculosis growth, can be considered an adjunctive therapy to anti-tuberculosis treatment (ATT). We determined whether metformin with standard ATT reduces time to sputum culture conversion and tissue inflammation in adults with pulmonary tuberculosis (PTB).
Methods: In a randomized, 8-week, clinical trial, newly diagnosed, culture-positive PTB patients were randomized to standard ATT (HREZ = control arm) or standard ATT plus daily 1000 mg metformin (MET-HREZ = Metformin with Rifampicin [METRIF] arm) for 8 weeks during 2018-2020 at 5 sites in India.